Zydus Lifesciences gains on getting EIR for formulations manufacturing facility in Moraiya from USFDA
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 444.15, up by 4.35 points or 0.99% from its previous closing of Rs. 439.80 on the BSE.
The scrip opened at Rs. 445.00 and has touched a high and low of Rs. 447.95 and Rs. 443.15 respectively. So far 6559 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 510.00 on 09-Nov-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 447.95 and Rs. 429.75 respectively. The current market cap of the company is Rs. 44516.74 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 15.53% and 9.49% respectively.
Zydus Lifesciences (including its subsidiaries, together referred to as ‘Zydus’), an innovation driven global lifesciences company has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility in Moraiya, near Ahmedabad, India. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). The USFDA had inspected the facility from July 26 to August 05, 2022 which concluded with four observations. The USFDA has indicated that the inspection is closed.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
